Results 91 to 100 of about 24,684 (197)

Treatment of age-related macular degeneration: focus on ranibizumab

Clinical Ophthalmology, 2008
Martin S Spitzer, Focke Ziemssen, Karl U Bartz-Schmidt, Faik Gelisken, Peter SzurmanTuebingen University Eye Center, University of Tuebingen, GermanyAbstract: Ranibizumab, a humanized antigen-binding fragment (Fab) that binds all isoforms of VEGF-A ...
Martin S Spitzer, Focke Ziemssen, Karl U Bartz-Schmidt, Faik Gelisken, Peter Szurman   +4 more
doaj  

The efficacy of ranibizumab treatment in clinical practice in patients with the wet form of age-related macular degeneration. The results of the Czech National Registry

Biomedical Papers, 2015
Aims: The aim of this communication was to evaluate ranibizumab in the treatment of wet age-related macular degeneration. Methods: Anonymised data on treatment efficacy and safety were consecutively entered into the Czech national database.
Oldrich Chrapek, Jiri Jarkovsky, Jan Studnicka, Martin Sin, Petr Kolar, Barbora Jirkova, Ladislav Dusek, Sarka Pitrova, Jiri Rehak   +8 more
doaj   +1 more source

DNA Nanoflower LYTACs Enable Efficient VEGF Degradation and Verteporfin Loading for Combined Therapy of Wet Age‐Related Macular Degeneration

Advanced Science, Volume 13, Issue 16, 18 March 2026.
An integrated approach that combines a DNA nanoflower VEGF degrader with photodynamic therapy is developed for the treatment of wet age‐related macular degeneration, which reduces the risk of VEGF reactivation‐induced CNV recurrence and minimizes the systemic side effects associated with photodynamic therapy.
Mengxuan Li, Yan Yue, Sijin Wu, Xinyu He, Jiayi Song, Shuwen Ma, Haokun Zhang, Chenyu Xu, Song Chen, Yanming Huang, Songbo Xie, Hua Yan   +11 more
wiley   +1 more source

Long-term follow-up of myopic choroidal neovascularization treated with ranibizumab [PDF]

, 2011
PURPOSE: To evaluate the long-term safety and efficacy of intravitreal ranibizumab in the treatment of myopic choroidal neovascularization (CNV). METHODS: Three-year retrospective, nonrandomized, interventional case series.
Cachulo, ML, Figueira, J, Fonseca, P, Franqueira, N, Marques, I, Pires, I, Silva, R   +6 more
core   +1 more source

Nanostructured drug delivery systems for posterior segment eye diseases: Strategies to defy ocular barriers

BMEMat, Volume 4, Issue 1, March 2026.
Efficient drug delivery to the posterior segment of the eye has long been a challenging issue due to the complex ocular barriers. The review focuses on the promise held by nanoplatforms for barrier penetration and the key mechanisms involved, also highlighting their advantages in achieving efficient drug delivery and superior treatment of PSEDs ...
Yifan Shen, Ying Yao, Yan Zhang, Xinyu Shi, Ling Bai, Yang Zhong, Yan Zhang, Kun Zhang   +7 more
wiley   +1 more source

Long-term effectiveness of ranibizumab for age-related macular degeneration and diabetic macular edema

Clinical Interventions in Aging, 2013
Angie HC Fong,1 Timothy YY Lai1,2 1Department of Ophthalmology and Visual Sciences, The Chinese University of Hong Kong, Hong Kong Eye Hospital, Kowloon, Hong Kong; 22010 Retina and Macula Centre, Tsimshatsui, Kowloon, Hong Kong Abstract: Neovascular ...
Fong AH, Lai TY
doaj  

Cost-effectiveness of ranibizumab versus aflibercept in the treatment of visual impairment due to diabetic macular edema: a UK healthcare perspective

ClinicoEconomics and Outcomes Research, 2015
Stephane A Régnier,1 William Malcolm,2 Jennifer Haig,3 Weiguang Xue41Novartis Pharma AG, Basel, Switzerland; 2Novartis Pharmaceuticals UK Ltd, Frimley Business Park, UK; 3Optum, Burlington, ON, Canada; 4Optum, Uxbridge, UKBackground: Ranibizumab ...
Régnier SA, Malcolm W, Haig J, Xue W   +3 more
doaj  

Switching to Faricimab or High‐Dose Aflibercept for Neovascular AMD in High‐Demand Patients: Impact on Injection Interval in a Real‐World Cohort

Clinical &Experimental Ophthalmology, EarlyView.
Zachary George Angus, Yin‐Zhi Lee, Sukhpal Singh Sandhu, Robyn Troutbeck, Jonathan Yeoh, Daniel Chiu, Manishka Jayasundera, Jaesser Tan, Sanjeewa Wickremasinghe   +8 more
wiley   +1 more source

A prospective pilot study comparing combined intravitreal ranibizumab and half-fluence photodynamic therapy with ranibizumab monotherapy in the treatment of neovascular age-related macular degeneration

Clinical Ophthalmology, 2012
Patrick D Williams,1 David Callanan,1 Wayne Solley,1 Robert L Avery,2 Dante J Pieramici,2 Tom Aaberg31Texas Retina Associates, Dallas, TX, 2California Retina Consultants and Research Foundation, Santa Barbara, CA, 3Retinal Associates, Grand Rapids, MI ...
Williams PD, Callanan D, Solley W, Avery RL, Pieramici DJ, Aaberg T   +5 more
doaj  

Combination of ranibizumab with photodynamic therapy vs ranibizumab monotherapy in the treatment of age-related macular degeneration:a systematic review and meta-analysis of randomized controlled trials

International Journal of Ophthalmology, 2014
AIM:To compare the efficacy and safety of combination of ranibizumab with photodynamic therapy (PDT) vs ranibizumab monotherapy in the treatment of age-related macular degeneration (AMD).METHODS:The Cochrane Central Register of Controlled Trials (CENTRAL)
Jun-Kang Si, Kai Tang, Hong-Sheng Bi, Da-Dong Guo, Jun-Guo Guo, Yu-Xiang Du, Yan Cui, Xue-Mei Pan, Ying Wen, Xing-Rong Wang   +9 more
doaj   +1 more source